Pharmaceutical companies have long cultivated ties with physicians, engaging them through drug detailing, consulting, and research arrangements.
1-3 However, the nature of these relationships and the magnitude of the dollars flowing from companies to physicians have largely been opaque to the public. Concerns about the influence of these financial relationships on physicians’ clinical decisions motivated Congress to include the Physician Payments Sunshine Act (PPSA) in the 2010 Patient Protection and Affordable Care Act.
4,5 The PPSA requires pharmaceutical and medical device firms to report, for public release, the payments and gifts of monetary value that they make to physicians. This public disclosure requirement was motivated by the belief that patients would become better informed about the potential influence of industry relationships on their physicians’ medical advice. Moreover, transparency might act as a deterrent to physicians accepting potentially suspect payments.
4,6